This page uses content from Wikipedia and is licensed under CC BY-SA.

Tranylcypromine/trifluoperazine

Tranylcypromine/trifluoperaizne
Combination of
TranylcypromineMonoamine oxidase inhibitor
TrifluoperazineTypical antipsychotic
Clinical data
Trade namesParstelin, Parmodalin, Jatrosom N, Stelapar
Routes of
administration
Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3] It is still available in Italy with the name of Parmodalin.[5]

See also

References

  1. ^ Richard C. Dart (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
  2. ^ Stephen M. Stahl (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
  3. ^ a b c Straker M, Grauer H (1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Can Med Assoc J. 85 (3): 127–30. PMC 1848140. PMID 20326829.
  4. ^ Lothar Bruno Kalinowsky; Hanns Hippius; Helmfried E. Klein (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
  5. ^ "SIT - Parmodalin". www.sit-farmaceutici.com. Retrieved 2016-04-18.